0000000000644639

AUTHOR

Erasmo Miele

showing 3 related works from this author

The pediatric endoscopy practice in Italy: A nationwide survey on behalf of the Italian society of pediatric gastroenterology, hepatology and nutriti…

2019

medicine.medical_specialtyAdolescentEndoscopy Digestive System Pediatrics Gastroenterology ItalyMEDLINENutritional StatusNationwide surveyPediatricsNOInternal medicinemedicineHumansEndoscopy Digestive SystemChildPediatric gastroenterologySocieties Medicaldigestive endoscopyPediatric endoscopyHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyInfant NewbornInfantNutritional statusEndoscopyHepatologyEndoscopyMulticenter studyItalypediatric endoscopy; digestive endoscopy; gastroenterologyFamily medicineChild PreschoolHealth Care SurveysPediatric endoscopybusinessDigestive System
researchProduct

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of…

2019

Patrizia Alvisi,1 Serena Arrigo,2 Salvatore Cucchiara,3 Paolo Lionetti,4 Erasmo Miele,5 Claudio Romano,6 Alberto Ravelli,7 Daniela Knafelz,8 Stefano Martelossi,9 Graziella Guariso,10 Salvatore Accomando,11 Giovanna Zuin,12 Costantino De Giacomo,13 Lucio Balzani,14 Monia Gennari,15 Marina Aloi3 On behalf of the SIGENP IBD Working Group 1Pediatric Gastroenterology Unit, Pediatric Department, Maggiore Hospital, Bologna, Italy; 2Pediatric Gastroenterology and Endoscopy Unit, G Gaslini Children’s Hospital, Genoa, Italy; 3Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy; 4Gastroenterology and Nutrition Unit, Meyer Children’s Hospital, Florenc…

medicine.medical_specialtyPopulationadalimumab efficacy03 medical and health sciences0302 clinical medicineadalimumab efficacy; adalimumab safety; infliximab failure; pediatric crohn’s diseaseRheumatologyInternal medicinemedicineAdalimumabinfliximab failureImmunology and AllergyTargets and Therapy [Biologics]Pharmacology (medical)Adverse effecteducationPediatric gastroenterologyOriginal ResearchCrohn's diseaseeducation.field_of_studybusiness.industryAdalimumab efficacy; Adalimumab safety; Infliximab failure; Pediatric Crohn’s disease; Immunology and Allergy; Rheumatology; Oncology; Gastroenterology; Pharmacology (medical)Gastroenterologyadalimumab safetyHepatologymedicine.diseaseInfliximabOncology030220 oncology & carcinogenesisCohortpediatric Crohn’s disease030211 gastroenterology & hepatologybusinessmedicine.drugBiologics : Targets & Therapy
researchProduct

Epidemiological trends of pediatric IBD in Italy: A 10-year analysis of the Italian society of pediatric gastroenterology, hepatology and nutrition r…

2022

Introduction: The present study aimed at evaluating Italian epidemiological trends of pediatric inflammatory bowel diseases (IBD) over the period 2009–2018. Materials and methods: Data from 1969 patients enrolled in the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition Registry, by 49 pediatric IBD centers throughout the country, were analyzed, comparing three different time intervals (2009–2012, 2013–2015, 2016–2018). Results: The number of new IBD diagnoses ranged from 175 to 219 per year, evenly distributed over the examined period of time. From 2009 to 2018, the minimal incidence ranged from 1.59 to 2.04 /105 inhabitants aged < 18 years, with an overall slight p…

RegistrieDelayed DiagnosisHepatologyDelayed DiagnosiGastroenterologyPediatric IBDEpidemiological trendInflammatory Bowel DiseasesSettore MED/38 - Pediatria Generale E SpecialisticaCrohn DiseaseItalyEpidemiological trendsHumansColitis UlcerativeRegistriesChildEpidemiological trends; Italy; Pediatric IBDHuman
researchProduct